Nuvalent Inc Cl A (NUVL) Stock Price, Quote & News

Company Profile

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) wh...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 357 7000

Website: www.nuvalent.com

Address:

One Broadway, 14th Floor, Cambridge, United States

BillionerOfKing Dec. 5 at 12:02 AM

$NUVL Current Stock Price: $106.84 Contracts to trade: $105 NUVL Dec 19 2025 Call Entry: $2.70 Exit: $3.79 ROI: 40% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

BEATOFtheMARKET Dec. 3 at 10:39 AM

$NUVB $NUVL $NVDA $NVDG $NVDL Undeniable Accuracy 🔥 Only if you too blind too see 🔥 Cycle Trading Signal plugged into AI 🔥 lists 🔥

0 · Reply

inflect1on Dec. 2 at 7:10 AM

$NUVL on watch rest of week

0 · Reply

Night_Owl_Biotech Nov. 30 at 2:04 AM

The attached graph compares $NUVL analyst consensus revenue estimates to the same for $MRUS as of the date the acquisition was announced and versus the revenue forecast MRUS provided $GMAB when GMAB agreed to acquire MRUS for an enterprise value of roughly $7.3B. NUVL's market cap is roughly $8.4B per Yahoo Finance. With roughly $1B cash, NUVL's enterprise value is $7.4B. This is not investment advice. We're merely sharing an observation. Just to be clear, note analysts have higher revenue estimates for NUVL in the outer years. $XBI $IBB

0 · Reply

Sw1ngb0t Nov. 26 at 10:16 PM

$CYPH $PGEN $NUVB $NUVL $LBRT

0 · Reply

JarvisFlow Nov. 24 at 6:00 PM

Truist Securities has updated their rating for Nuvalent ( $NUVL ) to Buy with a price target of 140.

0 · Reply

Sw1ngb0t Nov. 23 at 9:22 PM

$CYPH $URGN $NUVL on their way

0 · Reply

BEATOFtheMARKET Nov. 23 at 3:36 PM

$NUVB 🔥 $NUVL $NVDA $NVDG $NVDL

0 · Reply

Sw1ngb0t Nov. 22 at 1:00 AM

$CYPH $PGEN $NUVB $AMTM $NUVL

0 · Reply

JFais Nov. 21 at 9:00 PM

$NUVB $NUVL 🤣

1 · Reply

Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 4:01 PM EST - 10 days ago

Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders

Nov 19, 2025, 4:19 PM EST - 15 days ago

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

Nov 19, 2025, 11:56 AM EST - 16 days ago

Biotech Stock Gets Booted in Latest Fund Update

Nov 18, 2025, 11:50 PM EST - 16 days ago

Nuvalent Announces Pricing of Public Offering of Common Stock

Nov 17, 2025, 4:01 PM EST - 17 days ago

Nuvalent Announces Public Offering of Common Stock

Nov 17, 2025, 3:47 PM EST - 17 days ago

Nuvalent, Inc. (NUVL) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer Transcript

Nov 17, 2025, 1:03 PM EST - 17 days ago

Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer

Nov 17, 2025, 6:30 AM EST - 18 days ago

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

Nov 14, 2025, 4:01 PM EST - 20 days ago

Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib

Nov 4, 2025, 9:28 PM EST - 4 weeks ago

Nuvalent: Interesting Product, But Aggressive Valuation

Nov 4, 2025, 5:12 PM EST - 4 weeks ago

Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

Oct 30, 2025, 6:30 AM EDT - 5 weeks ago

Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results

Oct 18, 2025, 6:00 AM EDT - 6 weeks ago

Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025

Oct 13, 2025, 12:53 PM EDT - 7 weeks ago

Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 1, 2025, 6:22 PM EDT - 2 months ago

Nuvalent, Inc. (NUVL) Presents at UBS Virtual Oncology Day Transcript

Sep 24, 2025, 6:30 AM EDT - 2 months ago

Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

Sep 7, 2025, 4:45 AM EDT - 3 months ago

Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025

Aug 28, 2025, 6:30 AM EDT - 3 months ago

Nuvalent to Participate in the Cantor Global Healthcare Conference 2025

Aug 13, 2025, 1:06 PM EDT - 4 months ago

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

Aug 7, 2025, 8:18 AM EDT - 4 months ago

Nuvalent (NUVL) Q2 R&D Up 65%

Aug 7, 2025, 6:30 AM EDT - 4 months ago

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

Jul 21, 2025, 6:30 AM EDT - 4 months ago

Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC

Jun 24, 2025, 6:30 AM EDT - 5 months ago

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

Jun 23, 2025, 4:30 PM EDT - 5 months ago

Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib

Jun 18, 2025, 4:30 PM EDT - 6 months ago

Nuvalent Appoints Christy Oliger to Board of Directors

May 8, 2025, 7:31 AM EDT - 7 months ago

Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 1:09 PM EDT - 7 months ago

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

Apr 23, 2025, 10:28 AM EDT - 8 months ago

Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting

Apr 1, 2025, 6:30 AM EDT - 8 months ago

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Mar 25, 2025, 5:24 PM EDT - 9 months ago

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

Feb 28, 2025, 6:30 AM EST - 10 months ago

Nuvalent to Participate in Upcoming March Investor Conferences

Feb 27, 2025, 6:30 AM EST - 10 months ago

Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 6:30 AM EST - 11 months ago

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

Jan 10, 2025, 1:22 PM EST - 11 months ago

Nuvalent: A Logical Acquisition Target

Dec 19, 2024, 6:30 AM EST - 1 year ago

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 6:30 AM EST - 1 year ago

Nuvalent Appoints Grant Bogle to Board of Directors

Nov 26, 2024, 6:52 AM EST - 1 year ago

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 6:30 AM EST - 1 year ago

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Sep 23, 2024, 12:34 PM EDT - 1 year ago

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

Sep 17, 2024, 1:20 PM EDT - 1 year ago

Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases

Sep 16, 2024, 10:23 PM EDT - 1 year ago

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Sep 16, 2024, 1:44 PM EDT - 1 year ago

Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity

Sep 16, 2024, 11:18 AM EDT - 1 year ago

Cancer Biotech Nuvalent's Stock Jumps on Positive Data

Sep 14, 2024, 5:00 AM EDT - 1 year ago

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Sep 13, 2024, 9:53 AM EDT - 1 year ago

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Sep 9, 2024, 6:30 AM EDT - 1 year ago

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

Aug 29, 2024, 6:30 AM EDT - 1 year ago

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

BillionerOfKing Dec. 5 at 12:02 AM

0 · Reply

BEATOFtheMARKET Dec. 3 at 10:39 AM

$NUVB $NUVL $NVDA $NVDG $NVDL Undeniable Accuracy 🔥 Only if you too blind too see 🔥 Cycle Trading Signal plugged into AI 🔥 lists 🔥

0 · Reply

inflect1on Dec. 2 at 7:10 AM

$NUVL on watch rest of week

0 · Reply

Night_Owl_Biotech Nov. 30 at 2:04 AM

0 · Reply

Sw1ngb0t Nov. 26 at 10:16 PM

$CYPH $PGEN $NUVB $NUVL $LBRT

0 · Reply

JarvisFlow Nov. 24 at 6:00 PM

Truist Securities has updated their rating for Nuvalent ( $NUVL ) to Buy with a price target of 140.

0 · Reply

Sw1ngb0t Nov. 23 at 9:22 PM

$CYPH $URGN $NUVL on their way

0 · Reply

BEATOFtheMARKET Nov. 23 at 3:36 PM

$NUVB 🔥 $NUVL $NVDA $NVDG $NVDL

0 · Reply

Sw1ngb0t Nov. 22 at 1:00 AM

$CYPH $PGEN $NUVB $AMTM $NUVL

0 · Reply

JFais Nov. 21 at 9:00 PM

$NUVB $NUVL 🤣

1 · Reply

Sw1ngb0t Nov. 20 at 10:48 PM

$CYPH $PGEN $NUVL $URGN high confidence in these

0 · Reply

Quantumup Nov. 20 at 12:33 PM

Citizens⬆️ $NUVB's PT to $10 from $8, reiterated at a Market Outperform, plus⬆️ safusidenib's PoS to 50%. $AGIO $AZN $PFE $NUVL RHHBY BMY Citizens JMP said in its note: Safusidenib, in Ph2 Japanese glioma study, significantly outperformed based on ORR, compared to the Ph3 INDIGO study of vorasidenib (Servier/Agios, NC). Nuvation Bio plans to move forward with safusidenib in a higher-grade glioma setting, which we think is a sensible path (details below). With the launch of Ibtrozi trending in the right direction and potential plans for safusidenib materializing, we maintain our Market Outperform rating and increase our price target to $10 from $8 (DCF-derived) based on a higher safusidenib PoS (50% vs. 20% prior).

0 · Reply

jb06000 Nov. 20 at 10:42 AM

We are still way undervalued. We should still do time 4 or 5. based on $NUVL valuation. we should already be at $30 a share.

0 · Reply

AStrokeOfLuck Nov. 20 at 12:38 AM

$NUVL

0 · Reply

Sw1ngb0t Nov. 19 at 11:56 PM

$CYPH $PGEN $NUVB $NUVL $VNDA

1 · Reply

JFais Nov. 19 at 10:23 PM

$NUVL- expect 2L approval for zidesamtinib in ROS1+ NSCLC in Sept, 1L perhaps follows by 2028 or so Will be several years before they have 1L follow-up even approaching $NUVB DoR 1.9-13.9 months in 39 patients March 2025 cutoff vs Ibtrozi's N of 160, median DoR of 50 months...

0 · Reply

JFais Nov. 19 at 3:33 PM

$NUVL still 4x EV vs $NUVB, despite 20% reduction in updated ORR for zidesamtinib (ESMO data excluded patients with concomitant driver mutations whereas IASLC update included all) Ibtrozi has higher ORR and intracranial response rate in cross trial comparison, 50-month PFS = long time to catch up in 1st line (if ever)

1 · Reply

Doozio Nov. 19 at 3:30 PM

$NUVB $NUVL Newton about to get da huckleberries thru da $$$ while roger is rocking 🐒🍌🧠⏰♾️

0 · Reply

Quantumup Nov. 19 at 11:12 AM

B.Riley🏁 $NUVB Buy/$12 $AZN $PFE $NUVL $RHBBY BMY B.Riley in its initiation report said:

0 · Reply

erevnon Nov. 18 at 6:18 PM

Goldman Sachs maintains Nuvalent $NUVL at Buy and raises the price target from $120 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Nov. 18 at 5:51 PM

Goldman Sachs updates rating for Nuvalent ( $NUVL ) to Buy, target set at 120 → 135.

0 · Reply

erevnon Nov. 18 at 5:19 PM

Baird maintains Nuvalent $NUVL at Outperform and raises the price target from $112 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Market Cap	7.63B
Revenue (ttm)	0.00
Net Income (ttm)	-260.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	423,000
Avg Vol	621,174
Day's Range	N/A - N/A
Shares Out	72.71M
Stochastic %K	39%
Beta	1.31
Analysts	Strong Sell
Price Target	$141.82